HCPCS
J9176
1 mg = 1 unit
Phase 1
Identify what you're billing
Confirm the combo regimen, calculate weight-based units, and document premedication.
EPd vs. ERd — the only two approved regimens FDA verified May 2026
Empliciti has no monotherapy indication. Confirm which combo before billing — the maintenance schedule differs by partner drug.
Elotuzumab targets SLAMF7 (Signaling Lymphocytic Activation Molecule F7), a glycoprotein expressed on myeloma cells and natural killer cells. Its activity in multiple myeloma depends on co-administration with an immunomodulatory drug (IMiD) plus dexamethasone. Two FDA-approved combinations exist:
| EPd | ERd | |
|---|---|---|
| Combo partners | Elotuzumab + pomalidomide + dexamethasone | Elotuzumab + lenalidomide + dexamethasone |
| FDA approval | November 6, 2018 | November 30, 2015 (initial approval) |
| Indication | R/R multiple myeloma after ≥2 prior therapies (must include lenalidomide and a proteasome inhibitor) | R/R multiple myeloma after 1–3 prior therapies |
| Loading phase | 10 mg/kg IV weekly × 8 doses (cycles 1–2) | 10 mg/kg IV weekly × 8 doses (cycles 1–2) |
| Maintenance | 20 mg/kg IV every 4 weeks (cycle 3+) | 10 mg/kg IV every 2 weeks (cycle 3+) |
| Cycle length | 28 days | 28 days |
| IMiD REMS | Pomalyst REMS | Lenalidomide REMS |
| IMiD prior auth | Separate PA for pomalidomide required | Separate PA for lenalidomide required |
The maintenance schedule is the most common billing-error vector. EPd doubles the dose
(10 → 20 mg/kg) and quadruples the interval (weekly → q4w). ERd keeps the dose flat (10 mg/kg)
but doubles the interval (weekly → q2w). Mixing these up will trigger PA denials and recoupments.
Single-agent elotuzumab claims will be denied. If the IMiD partner is held for toxicity,
elotuzumab should typically be held with it. Billing elotuzumab as monotherapy is off-label and
non-reimbursable across all major payers.
Dosing & unit math FDA label verified May 2026
Weight-based dosing means the unit count varies per patient. Reconcile vial draw against documented body weight before submitting.
Calculating units from weight
- 1 mg = 1 unit
- Loading dose units = patient weight (kg) × 10
- EPd maintenance units = patient weight (kg) × 20
- ERd maintenance units = patient weight (kg) × 10
- Bill the actual mg administered (the dose is calculated to the nearest mg per the FDA label; do not round to the vial)
| Patient weight | 10 mg/kg dose | 20 mg/kg dose | Vial combination (10 mg/kg) | Waste (10 mg/kg) |
|---|---|---|---|---|
| 60 kg | 600 units | 1,200 units | 2 × 300 mg | 0 mg (JZ) |
| 65 kg | 650 units | 1,300 units | 2 × 400 mg | 150 mg (JW) |
| 70 kg | 700 units | 1,400 units | 1 × 400 + 1 × 300 | 0 mg (JZ) |
| 80 kg | 800 units | 1,600 units | 2 × 400 mg | 0 mg (JZ) |
| 90 kg | 900 units | 1,800 units | 3 × 300 mg | 0 mg (JZ) |
| 100 kg | 1,000 units | 2,000 units | 1 × 400 + 2 × 300 mg | 0 mg (JZ) |
| 110 kg | 1,100 units | 2,200 units | 2 × 400 + 1 × 300 | 0 mg (JZ) |
Worked example — 80 kg patient on EPd, first 6 months
# Cycles 1–2 (loading): 10 mg/kg IV weekly × 8 doses
Dose: 80 kg × 10 mg/kg = 800 mg
Vials: 2 × 400 mg (zero waste → JZ)
Units billed per dose: 800 (J9176)
Cost per dose (Q2 2026 ASP+6%): 800 × $8.041 = $6,432.80
Loading total: 8 doses × $6,432.80 = $51,462.40
# Cycle 3+ (maintenance): 20 mg/kg IV every 4 weeks
Dose: 80 kg × 20 mg/kg = 1,600 mg
Vials: 4 × 400 mg (zero waste → JZ)
Units billed per dose: 1,600 (J9176)
Cost per dose (Q2 2026 ASP+6%): 1,600 × $8.041 = $12,865.60
Maintenance through month 6: 4 doses × $12,865.60 = $51,462.40
# 6-month total drug cost (Medicare ASP+6%)
~$102,925 before sequestration (admin + premeds billed separately)
Dose: 80 kg × 10 mg/kg = 800 mg
Vials: 2 × 400 mg (zero waste → JZ)
Units billed per dose: 800 (J9176)
Cost per dose (Q2 2026 ASP+6%): 800 × $8.041 = $6,432.80
Loading total: 8 doses × $6,432.80 = $51,462.40
# Cycle 3+ (maintenance): 20 mg/kg IV every 4 weeks
Dose: 80 kg × 20 mg/kg = 1,600 mg
Vials: 4 × 400 mg (zero waste → JZ)
Units billed per dose: 1,600 (J9176)
Cost per dose (Q2 2026 ASP+6%): 1,600 × $8.041 = $12,865.60
Maintenance through month 6: 4 doses × $12,865.60 = $51,462.40
# 6-month total drug cost (Medicare ASP+6%)
~$102,925 before sequestration (admin + premeds billed separately)
Variable-rate ramp-up — chair time matters
Per the FDA label, the cycle 1–2 first dose begins at 0.5 mL/min for the first 30 minutes, then 1 mL/min for 30 minutes, then 2 mL/min, escalating to a maximum of 5 mL/min if tolerated. Total infusion time during the loading phase commonly exceeds 90 minutes for higher volumes, requiring CPT 96415 (each additional hour) in addition to 96413. Cycle 3+ doses may run at 5 mL/min from the start once tolerance is confirmed.
Premedication checklist — required FDA label verified May 2026
Skipped premedication is both an audit finding and an infusion-reaction liability. Document each agent in the encounter.
Despite premedication, the infusion-reaction rate is approximately 10% with the first dose. The FDA label requires four agents 45–90 minutes before every Empliciti infusion:
| Agent | Dose & route | Notes |
|---|---|---|
| Dexamethasone | 8 mg PO + 4 mg IV (in addition to combo regimen dex) | Counts toward total cycle dex; coordinate with EPd/ERd dex schedule |
| Diphenhydramine | 25–50 mg PO or IV | Or equivalent H1 antihistamine |
| H2 blocker | Ranitidine 50 mg IV or famotidine 20 mg IV | Famotidine preferred (ranitidine withdrawn from US market 2020 — substitute famotidine) |
| Acetaminophen | 650–1,000 mg PO | Verify no hepatic contraindication |
Famotidine substitution. The FDA label still references ranitidine, but ranitidine
was withdrawn from the US market in April 2020 due to NDMA contamination. Famotidine 20 mg IV is
the standard practical substitute. Document the substitution in the order set.
Bill premed administration appropriately. If IV premeds are given before the chemo
infusion, they may qualify for hydration (96360/96361) or therapeutic IV push (96374) codes per
encounter documentation. Oral premeds are not separately billable but should be documented for
infusion-reaction defense.
NDC reference FDA NDC Directory verified May 2026
| NDC (10/11-digit) | Vial size | Use |
|---|---|---|
0003-3155-11 / 00003-3155-11 |
300 mg single-dose vial (lyophilized powder) | Used in combinations to minimize waste in patients ~60–90 kg |
0003-3156-11 / 00003-3156-11 |
400 mg single-dose vial (lyophilized powder) | Standard for 80 kg patients (10 mg/kg = 800 mg = 2 × 400 mg, zero waste) |
Reconstitution required. Both vials are lyophilized powder. Reconstitute with sterile
water for injection per label, then dilute in 0.9% NaCl or 5% Dextrose to a final concentration of
1–6 mg/mL for infusion. Do not shake; swirl gently. Use within timeframes specified in the label
(typically 24 hours refrigerated post-reconstitution).
Vial-combination optimization. Use the patient weight calculator to choose the
vial mix that minimizes waste. A 70 kg patient (700 mg) is best served by 1 × 400 + 1 × 300
(zero waste, JZ). A 65 kg patient (650 mg) requires 2 × 400 (150 mg waste, JW) or 1 × 400 +
1 × 300 with 50 mg waste (still JW). Pick the combination that yields the least waste per the
institution's pharmacy policy.
Phase 2
Code the claim
Chemo admin codes, weight-based modifier choice, and complete combo-regimen documentation.
Administration codes CPT verified May 2026
Elotuzumab is billed as chemotherapy administration; ramp-up regularly requires the additional-hour add-on.
| Code | Description | When to use |
|---|---|---|
96413 |
Chemotherapy administration, IV infusion technique; up to 1 hour, single or initial substance/drug | Primary code for Empliciti. Always billed for the first hour of the elotuzumab infusion. |
96415 |
Chemotherapy administration, IV infusion; each additional hour | Frequently needed during ramp-up. Bill one unit per additional 30+ minutes beyond the first hour, per documented chair time. Loading-phase doses commonly hit 90–120 minutes. |
96365 / 96366 |
Therapeutic IV infusion (non-chemo) | NOT appropriate for elotuzumab. CPT classifies elotuzumab admin under chemo codes per AMA guidelines for complex monoclonal antibody administration. |
96360 / 96361 |
IV hydration; initial 31–60 min / each additional hour | Optional for premedication delivery if hydration is documented as medically necessary. |
96374 |
IV push, single drug | For IV premedications (dex IV, diphenhydramine IV, famotidine IV) when given as separate pushes. |
Why chemo admin for a non-cytotoxic mAb: CPT chemotherapy administration codes
(96409–96425) apply to complex monoclonal antibody administration regardless of mechanism.
Elotuzumab qualifies because of the variable rate ramp-up, infusion-reaction risk, and required
premedication protocol — criteria the AMA uses to distinguish chemo admin from therapeutic IV.
Modifiers CMS verified May 2026
JZ — no waste
Use JZ when the calculated dose matches the vial combination exactly. Examples: an 80 kg patient on the loading dose (800 mg = 2 × 400 mg vials) or a 90 kg patient on the loading dose (900 mg = 3 × 300 mg vials). Effective July 1, 2023, CMS requires JZ on every single-dose container claim with no discarded drug.
JW — partial-vial waste
Use JW on a separate claim line to report the discarded portion. Example: a 65 kg patient receiving the 10 mg/kg loading dose needs 650 mg, drawn from two 400 mg vials (800 mg) with 150 mg discarded. Bill J9176 with 650 units (JZ on administered) AND a separate line with 150 units (JW on waste). Reconcile vial draw vs documented body weight before submitting — weight-based dosing means waste is the rule, not the exception.
One of JZ or JW must be on every J9176 claim. CMS audits frequently catch missing
JW on weight-based drugs like elotuzumab. The wasted drug is reimbursable but must be reported on
its own line with appropriate modifier and units.
Modifier 25 — same-day E/M
Use modifier 25 on the E/M code when a significant, separately identifiable evaluation and management service (e.g., infusion-reaction assessment, performance status check) is performed on the same day as the infusion. Routine pre-infusion clinical assessment is bundled into the chemo admin code.
340B modifiers (JG, TB)
For 340B-acquired Empliciti, follow your MAC's current 340B modifier policy. BMS's billing guide does not provide 340B-specific instructions for elotuzumab.
ICD-10-CM — multiple myeloma family FY2026 verified May 2026
Empliciti's only approved indications are in relapsed/refractory multiple myeloma.
| Code | Indication | Notes |
|---|---|---|
C90.00 | Multiple myeloma, NOS, not having achieved remission | Default for newly relapsed disease without prior remission documentation |
C90.01 | Multiple myeloma, in remission | Use for maintenance phase claims when patient is in clinical/serologic remission |
C90.02 | Multiple myeloma, in relapse | Most common code at therapy initiation — documents relapse from prior response |
C90.30 | Solitary plasmacytoma | Not approved for Empliciti |
C88.0 | Waldenström's macroglobulinemia | Not approved for Empliciti |
Indication code drives PA approval. Most payers require C90.00, C90.01, or C90.02
plus documentation of prior therapies (1–3 prior lines for ERd; ≥2 prior lines including
lenalidomide and a proteasome inhibitor for EPd). Submit the prior-therapy summary with the PA.
Companion ICD-10 codes often accompany myeloma claims and may be needed for ancillary
services:
D63.0 (anemia in MM), N18.x (CKD from cast nephropathy),
M89.7x (lytic bone lesions). These do not substitute for the primary C90 code.
Site of care & place of service Verified May 2026
UnitedHealthcare and major BCBS plans run aggressive site-of-care UM for myeloma antineoplastics, including elotuzumab. The combo-therapy model and ramp-up infusion time make Empliciti chair-intensive — HOPD is often required during loading phase but disfavored once the patient stabilizes.
| Setting | POS | Claim form | Payer steering |
|---|---|---|---|
| Physician oncology office | 11 | CMS-1500 / 837P | Preferred by commercial UM after stable |
| Ambulatory infusion suite (AIC) | 49 | CMS-1500 / 837P | Preferred by commercial UM after stable |
| Oncology ASC | 24 | CMS-1500 / 837P | Acceptable |
| Hospital outpatient (on-campus) | 22 | UB-04 / 837I | Often acceptable during loading; disfavored for maintenance |
| Hospital outpatient (off-campus PBD) | 19 | UB-04 / 837I | Disfavored after first ~3 months |
| Patient home | 12 | CMS-1500 (with home infusion) | Rare for IV oncology with infusion-reaction risk |
Loading-phase chair time is real. The variable-rate ramp-up plus 45–90 min
premedication setup commonly produces 3+ hour total chair times during the first cycle. Plan
scheduling and site-of-care accordingly.
Claim form field mapping BMS Access Support 2026
From BMS Access Support — Empliciti coding & coverage HCP page.
| Information | CMS-1500 box | Notes |
|---|---|---|
| NPI | 17b | Rendering provider |
| NDC qualifier + 11-digit NDC + UoM + qty | 24A shaded area | N4 + carton NDC + UN (units, since reconstituted) or ML if documented |
| HCPCS J9176 + JZ (administered units) | 24D (drug line) | Patient weight (kg) × 10 or 20 |
| HCPCS J9176 + JW (wasted units) | 24D (separate drug line, only when applicable) | Discarded mg only — do NOT combine with administered units on same line |
| Drug units | 24G | Actual mg administered (and separate JW line if applicable) |
| CPT 96413 (admin line) | 24D (admin line) | First hour of chemo IV |
| CPT 96415 (additional hours) | 24D (admin line) | Each additional hour beyond the first — common during loading |
| ICD-10 | 21 | C90.00, C90.01, or C90.02 |
| PA number | 23 | Required by all major payers; separate PA also needed for IMiD partner |
Phase 3
Get paid
Three-drug PA stack (elotuzumab + IMiD + REMS), Medicare ASP, BMS support resources.
Payer policy snapshot + REMS coordination Reviewed May 2026
Empliciti is a three-drug stack with two REMS programs — coordinate before scheduling the first infusion.
| Payer | PA? | Combo enforcement | Site-of-care UM |
|---|---|---|---|
| UnitedHealthcare Oncology Med Coverage Policy |
Yes (all MM antineoplastics) | Strict: requires combo regimen documentation, prior-therapy summary, and active IMiD prescription | Yes — Optum-managed steering away from HOPD after loading phase |
| Aetna CPB + Medical Drug policies |
Yes | Requires EPd or ERd combo; prior-line documentation; REMS enrollment confirmation for IMiD partner | Yes (separate Site-of-Care policy) |
| BCBS plans Vary by plan |
Yes | Generally aligned with NCCN MM Guidelines + FDA label combo definitions | Plan-specific; most have site-of-care steering |
| Medicare (Part B) MAC LCDs |
No PA, but documentation | MAC LCDs cover EPd and ERd combos for FDA-labeled R/R MM lines of therapy | Not steered, but MAC may audit |
REMS coordination — do not skip
- Empliciti itself has no REMS program.
- Lenalidomide REMS (for ERd): patient + prescriber + pharmacy enrollment; monthly authorization for each refill.
- Pomalyst REMS (for EPd): patient + prescriber + pharmacy enrollment; monthly authorization for each refill.
- If the IMiD REMS is not active, the elotuzumab infusion should be deferred — the patient cannot complete the regimen.
Step therapy
Elotuzumab is positioned as a later-line option in NCCN guidelines. Most payers require documented progression on or intolerance to a daratumumab-based regimen and/or carfilzomib before approving elotuzumab combos in some lines. Verify per-payer; ERd is also commonly stepped behind daratumumab (Darzalex) + Rd.
Medicare reimbursement CMS Q2 2026 (live)
Quarterly ASP from CMS Part B Drug Pricing File. Refreshes automatically each quarter.
Q2 2026 payment snapshot — J9176
Effective April 1 – June 30, 2026 · Based on 4Q25 ASP submissions
ASP + 6%
$8.041
per mg / per unit
800 mg loading dose (80 kg)
$6,432.80
800 units × ASP+6%
1,600 mg EPd maintenance (80 kg)
$12,865.60
1,600 units × ASP+6%
Annualized cost (80 kg patient on EPd): 8 loading doses (~$51,500) + ~12 maintenance
doses/year at 1,600 mg (~$154,400) = ~$200,000+/year elotuzumab alone (Medicare
ASP+6%), before pomalidomide and dexamethasone. After ~2% sequestration: ~$196,000/year actual paid.
ERd patient at 80 kg sees a different mix — 26 doses/year of 800 mg (~$167,250).
Coverage
No NCD specific to elotuzumab. Coverage falls under MAC LCDs for biologic antineoplastics + the CMS off-label compendia framework. All MACs cover J9176 for FDA-approved EPd and ERd combos with appropriate ICD-10 (C90.0x) and prior-therapy documentation.
Code history
- J9176 — permanent code, "Injection, elotuzumab, 1 mg." Initial FDA approval was November 30, 2015 (BLA 761035) for the ERd combo; the EPd combo was added November 6, 2018. The permanent J-code replaced earlier unclassified J3490/J9999 billing.
Patient assistance — BMS Access Support BMS verified May 2026
- BMS Access Support: 1-800-861-0048 / bmsaccesssupport.com — benefits investigation, prior authorization assistance, appeal support, and combo-regimen coordination
- Empliciti Co-Pay Assistance Program: commercial copay support up to $25,000 per year for elotuzumab; eligible commercially-insured patients only (excludes Medicare, Medicaid, federal program patients)
- BMS Patient Assistance Foundation: free product for uninsured / underinsured patients meeting income requirements (administered through the BMS Patient Assistance Foundation, Inc., a 501(c)(3))
- IMiD partner support: Pomalyst and Revlimid have separate BMS support programs; coordinate enrollments simultaneously
- Foundations for Medicare patients: refer to PAN, HealthWell, CancerCare, Leukemia & Lymphoma Society — verify open multiple myeloma funds quarterly
- Web: empliciti.com · bmsaccesssupport.com
Need to model what a specific patient will actually pay across the three-drug stack after copay
assistance, deductible, coinsurance, and OOP max?
Run a CareCost Estimate — J9176 pre-loaded.
Phase 4
Fix problems
M-protein interference, weight-based JW errors, and missing combo documentation.
M-protein measurement interference FDA label W&P verified May 2026
A clinical-quality issue, not a billing issue — but it surfaces in audits when response assessment is challenged.
Elotuzumab is a humanized IgGκ monoclonal antibody. Standard serum protein electrophoresis (SPEP) and immunofixation electrophoresis (IFE) used to track M-protein in multiple myeloma cannot reliably distinguish circulating therapeutic elotuzumab from a patient's native M-protein. The interference is most pronounced in patients with IgGκ isotype myeloma (the most common subtype), where therapeutic and disease antibody migrate similarly on the gel.
Action required: alert the lab. The lab must know the patient is on elotuzumab so
they can apply specialized assays (e.g., HYDRASHIFT-type immunofixation that shifts therapeutic
antibody out of the diagnostic zone, or mass-spectrometry-based methods like MALDI-TOF) when needed.
Document the lab notification in the chart at therapy initiation and at every transition (e.g., from
loading to maintenance).
Why this matters for billing audits. When a payer audits an Empliciti claim for medical
necessity (e.g., "is the patient still responding?") they look for a clean M-protein response curve.
Apparent stable disease that is actually deeper response masked by therapeutic antibody can trigger
denial of continuation. Document the lab's interference-aware methodology and the corrected M-protein
values to defend the claim.
Common related errors
- Sending SPEP/IFE without alerting the lab — results may be misinterpreted
- Using uncorrected M-protein for response assessment in IgGκ patients
- Failing to document lab-notification in the patient's chart at therapy initiation
Common denials & how to fix them
| Denial reason | Common cause | Fix |
|---|---|---|
| Off-label monotherapy | Elotuzumab billed without IMiD partner active | Empliciti is combo-only. Document concurrent pomalidomide (EPd) or lenalidomide (ERd) active prescription. Resubmit with IMiD pharmacy fill record. |
| Missing JW on weight-based dose | Wasted drug not reported when partial vial discarded | Add JW line for discarded units. JZ on the administered units; JW on the wasted units. Reconcile vial draw vs documented kg. |
| Wrong maintenance schedule | EPd billed q2w 10 mg/kg or ERd billed q4w 20 mg/kg | EPd = 20 mg/kg q4w. ERd = 10 mg/kg q2w. Confirm regimen with prescribing oncologist before resubmission. |
| Wrong admin code (96365) | Therapeutic IV billed instead of chemo IV | Resubmit with 96413 + 96415 add-on hours. Elotuzumab is chemo admin per CPT classification. |
| No premedication documented | Premed orders missing from encounter note | Document the four required agents (dex, diphenhydramine, H2 blocker, acetaminophen) given 45–90 min before infusion. Submit corrected encounter. |
| JZ missing on adult claim with no waste | Single-dose vial claim without JZ | Resubmit with JZ. Required since 7/1/2023 on every claim with no discarded drug. |
| IMiD REMS not enrolled | Elotuzumab approved but pomalidomide/lenalidomide REMS not active | Cannot proceed with infusion. Enroll patient/prescriber/pharmacy in Lenalidomide REMS or Pomalyst REMS before scheduling. |
| Prior-therapy criteria not met | EPd billed without ≥2 prior lines including len + PI; ERd billed beyond 1–3 prior lines | Submit complete prior-therapy summary with line-of-therapy documentation. Confirm regimen matches FDA-approved indication. |
| M-protein response not interpretable | Continuation denial because response curve appears flat | Submit lab-corrected M-protein values using interference-aware assay (HYDRASHIFT or mass-spec). Document lab notification in chart. |
Frequently asked questions
What is the HCPCS code for Empliciti?
Empliciti (elotuzumab) is billed under HCPCS J9176 — "Injection, elotuzumab,
1 mg." Each milligram equals one billable unit. Because dosing is weight-based, the unit count
varies per patient: an 80 kg patient on the 10 mg/kg loading dose is billed for 800 units; the
same patient on 20 mg/kg EPd maintenance is billed for 1,600 units.
Can Empliciti be given as monotherapy?
No. Empliciti is FDA-approved only in combination — never as monotherapy. The two approved regimens are ERd (elotuzumab + lenalidomide + dexamethasone) for R/R MM after 1–3 prior therapies, and EPd (elotuzumab + pomalidomide + dexamethasone) for patients with ≥2 prior therapies including lenalidomide and a proteasome inhibitor. Single-agent elotuzumab claims will be denied as off-label.
How do EPd and ERd dosing schedules differ?
Both regimens use the same loading: 10 mg/kg IV weekly × 8 doses (cycles 1–2). Maintenance differs. EPd escalates to 20 mg/kg IV every 4 weeks starting cycle 3. ERd stays at 10 mg/kg IV every 2 weeks starting cycle 3. The maintenance schedule is the most common billing-error vector.
What administration CPT do I use for Empliciti?
96413 for the first hour of chemo IV plus 96415 for each additional hour.
The variable-rate ramp-up (cycle 1–2 first dose starts at 0.5 mL/min, escalating to 5 mL/min
if tolerated) regularly takes the loading-phase infusions past 60 minutes. Cycle 3+ doses may infuse
at 5 mL/min throughout. Do NOT use 96365.
Is premedication required for Empliciti?
Yes — required by the FDA label. The high baseline infusion-reaction rate (~10% with the first dose despite premedication) makes the protocol non-negotiable. Administer 45–90 minutes before each infusion: dexamethasone (8 mg PO + 4 mg IV in addition to combo dex), diphenhydramine 25–50 mg PO/IV, H2 blocker (famotidine 20 mg IV preferred over withdrawn ranitidine), acetaminophen 650–1,000 mg PO. Document each premed in the encounter.
What is the Medicare reimbursement for J9176?
For Q2 2026, the Medicare Part B payment limit for J9176 is $8.041 per mg (ASP + 6%). The 10 mg/kg loading dose for an 80 kg patient (800 mg) reimburses at approximately $6,432.80; the 20 mg/kg EPd maintenance dose for the same patient (1,600 mg) reimburses at approximately $12,865.60. Annualized for an 80 kg EPd patient: ~$200,000+/year. Sequestration (~2%) reduces actual paid to roughly ASP + 4.3%.
Do I bill JZ or JW for Empliciti?
One of JZ or JW must be on every J9176 claim. Because dosing is weight-based and the only available vial sizes are 300 mg and 400 mg single-dose, partial-vial waste is the rule rather than the exception. Examples: an 80 kg patient on the 10 mg/kg loading dose (800 mg = 2 × 400 mg) bills JZ for 800 units. A 65 kg patient on the same regimen (650 mg) using 2 × 400 mg vials bills JZ for 650 administered units AND JW on a separate line for 150 units of waste.
Why does Empliciti interfere with M-protein measurement?
Elotuzumab is a humanized IgGκ monoclonal antibody. Standard SPEP and IFE cannot reliably distinguish therapeutic elotuzumab from a patient's own M-protein, especially in IgGκ myeloma. This can confound response assessment. The lab must be alerted that the patient is on elotuzumab so they can apply HYDRASHIFT-type assays or mass-spectrometry-based methods. Document the lab notification in the chart — this is a frequent audit finding.
Reference
Sources & methodology
Every claim on this page is sourced. Methodology and review history below.
Source documents
- BMS — Empliciti (elotuzumab) Prescribing Information (FDA label)
- DailyMed — EMPLICITI (elotuzumab)
- Empliciti — HCP coding & coverage page
- BMS Access Support — Empliciti benefits investigation, PA, appeals
- CMS — Medicare Part B Drug ASP Pricing File
- NCCN Clinical Practice Guidelines in Oncology — Multiple Myeloma
- SEER CanMED — HCPCS J9176 reference
- UnitedHealthcare — Oncology Medication Clinical Coverage Policy (covers MM antineoplastics including elotuzumab)
- FDA National Drug Code Directory
- FDA — Ranitidine market withdrawal (April 2020)
- Lenalidomide REMS · Pomalyst REMS
About this page
We maintain this page as a living reference. Medicare ASP pricing is bound to our underlying CareCost data layer and refreshes automatically when CMS publishes new quarterly files. Coding and policy content is reviewed at least quarterly and updated whenever a source document changes.
Found an error? Email hello@carecostestimate.com.
Refresh cadence
| Element | Cadence | How it's refreshed |
|---|---|---|
| Medicare ASP pricing | Quarterly | Auto-bound to CareCost ASP layer; updates on CMS file release. |
| Payer policies (UHC, Aetna, BCBS, Medicare LCDs) | Semi-annual | Manual review against published payer policy documents and MAC LCDs. |
| HCPCS / CPT / modifier rules | Annual | Reviewed against CMS HCPCS quarterly files and AMA CPT releases. |
| NDC, dosing, FDA label, premedication protocol | Event-driven | Tied to BMS package insert version + FDA label revision date. Empliciti label is stable; ranitidine substitution noted independently. |
| REMS coordination (IMiD partners) | Annual | Reviewed against current Lenalidomide REMS and Pomalyst REMS materials. |
Reviewer
Pending SME review. This page is staff-authored from primary sources (FDA label,
BMS Access Support, CMS, NCCN, payer policy documents — all linked above). Final review by our
SME, the CareCost editorial team, is in progress. Until that review is complete, treat this as a draft
reference and verify each cited source for high-stakes claims.
Change log
- — Initial publication. ASP data: Q2 2026. Manufacturer source: BMS Access Support 2026 (package insert + HCP coding & coverage page). FDA label: most recent revision. Two combos covered: ERd (Nov 2015 approval) and EPd (Nov 2018 approval). M-protein interference, premedication checklist, and famotidine-for-ranitidine substitution noted.
Methodology
Every claim on this page is sourced inline. Pricing reflects the current CMS Part B Drug ASP Pricing File. Payer policies are read directly from each payer's published medical/pharmacy policy documents. Dosing and premedication content is verified against the BMS Empliciti package insert. We do not paraphrase from billing-software vendor blogs.